BioSpace News Archive

BIOLASE, Inc., the global leader in dental lasers, announced that it is inviting clinicians and researchers from around the world to submit research proposals via the Research Grant Portal at biolase.com/researchgrants.

Zimmer Biomet Holdings, Inc. announced its third quarter earnings conference call will be webcast on Wednesday, November 2, 2022 at 8:30 a.m. ET.

Molecular Testing Labs, a mission-driven, innovative health sciences company specializing in clinical diagnostics, announced they have selected Jason Hall as their Chief Financial Officer.

Endo International plc announced the launch of its new branded video series, Coffee & Cords, which aims to educate people about Dupuytren’s contracture, a progressive hand condition that results in the formation of a collagen rope-like cord that pulls fingers toward the palm and affects an estimated 14 million Americans.

Asahi Kasei, a diversified Japanese multinational company, and subsidiary Crystal IS have concluded in a bacterial performance test that an experimental Klaran™ WR water treatment reactor demonstrated over 75% higher performance than a traditional low pressure mercury lamp system using an equivalent power consumption level.

ALX Oncology Holdings Inc. announced the acceptance of two Trials in Progress abstracts related to ASPEN-03 and ASPEN-04, the Company’s Phase 2 head and neck cancer studies in collaboration with Merck, at the SITC 37th Annual Meeting in Boston, MA, from November 8–12, 2022.

Massive Bio, a leader in AI-powered cancer clinical trial enrollment, announced a strategic partnership with Perthera.ai, a pioneer in connecting oncologists and patients with biomarker-based therapy options.

Valitor, a biotechnology company engineering better medicines to conquer drug limitations, announced that it has closed a Series B financing and named Steven Lo as chief executive officer and member of the board.

Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. that is focused on developing ultra-high concentration nitric oxide for the treatment of solid tumors, announced that the Company will present data at the upcoming Society for Immunotherapy of Cancer Annual Meeting 2022, which is scheduled to be held November 8-12, at the Boston Convention & Exhibition Center in Boston, Massachusetts.

Genenta Science, a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, will present at several upcoming scientific and investor conferences.